5-aza-2-deoxycytidine With Pegylated Interferon-alfa 2B: A Phase I Study With Molecular Correlates
Status:
Terminated
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess toxicities of a 1-hr infusion of
5-aza-2'-deoxycytidine (decitabine) x 10 days (M-F) plus escalating doses of weekly
subcutaneous PEG-interferon-α (PEG-Intron) in patients with metastatic cancer and to identify
the maximum tolerated dose of PEG-Intron in this combination. The pre- and post-treatment
samples will be evaluated to identify changes in molecular correlates.
Phase:
Phase 1
Details
Lead Sponsor:
Nevada Cancer Institute
Collaborators:
National Institutes of Health (NIH) Schering-Plough